Insights Into the Management of Lower-Risk Myelodysplastic Syndromes (LR-MDS)
Perspectives on treatment decisions across first-line and subsequent-line therapies in LR-MDS by community oncologists.
Central – March 27, 2026
Faculty Chair
Yazan Madanat, MD
UT Southwestern Medical Center, Dallas, TX, USA
Insights Obtained From
- Louisiana, Missouri, Texas
REPORT SNAPSHOT
- First-line treatment of LR-MDS
- Subsequent-line therapy in LR-MDS
- Detailed insights and attendee takeaways
- ARS data
GEOGRAPHIC REPRESENTATION AND CONTENT DEVELOPMENT
- Data collection was accomplished through the use of audience response system questioning and moderated discussion
- The group of experts comprised 10–15 community oncologists representative of each region
Purchase Report
Thank you for your interest in our insights.
Complete the form below to receive additional information.